
Keywords: Adverse drug events; Effectiveness; Exacerbations; Omalizumab; Severe asthma; ADRs; adverse drug reaction; AEs; adverse events; GETE; global evaluation of treatment effectiveness; GINA; Global Initiative for Asthma; HCRU; health care resource utilization;